-
MM-associated AL Amyloidosis_Shaji Kumar, MD
53:27
-
How to Integrate Novel Approaches in the Treatment of Relapsed/Refractory Myeloma_Suzanne Lentzch, MD, PhD; #hemeupdates2022
15:29
-
New Data in Upfront Management of Multiple Myeloma_Ruben Niesvizky, MD; #hemeupdates2022
12:34
-
New data in upfront management of multiple myeloma_Sagar Lonial, MD; #BeyondTheCongress
14:31
-
What are the latest approaches for using CAR T-cell therapy in multiple myeloma?_Nina Shah, MD; #BeyondTheCongress
15:16
-
Virtual Challenging Case Clinic: Multiple Myeloma - Updates from ASH_Krina Patel, MD, MSc
55:01
-
Round 3: What is the Optimal Class of Agents for Triple Class Refractory MM?_Sagar Lonial, MD, FACP and Saad Usmani, MD, MBA, FACP
24:44
-
Q&A: Experts Debate: Treatment Decisions in Relapsed Refractory Multiple Myeloma_Sagar Lonial, MD, FACP_Jonathan Kaufman, MD_Krina Patel, MD, MSc_Saad Usmani, MD, MBA, FACP
28:11
-
Round 4: What is the Optimal Immunotherapy for Targeting BCMA?_Krina Patel, MD, MSc and Jonathan Kaufman, MD
27:57
-
Round 1: What is the Optimal Partner for CD38 Therapy in First Relapse_Jonathan Kaufman, MD and Saad Usmani, MD, MBA, FACP
29:23
-
Round 2: Is MRD Assessment Useful for Treatment Decisions?_Krina Patel, MD, MSc and Sagar Lonial, MD, FACP
27:57
- Next Page